A Phase I, Prospective, Open Label Clinical Study to Assess the Safety and Immunogenicity of DTwP-HepB-IPV-Hib Vaccine Manufactured by SIIPL in Healthy Toddlers aged 16-24 Months
Latest Information Update: 10 Dec 2020
At a glance
- Drugs Hib-DTP-hepatitis B-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors Serum Institute of India
- 02 Dec 2020 Status changed from not yet recruiting to completed.
- 12 Nov 2018 New trial record